PIM
ALXN

Platinum Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Platinum Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-646
Closed -$74K – 157
2020
Q3 		$74K Buy
+646
New +$69.7K ﹤0.01% 131

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Platinum Investment Management's ALXN Position: Q4 2020 in Review

Platinum Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 646 shares — an estimated $74K sold.

Platinum Investment Management first reported a position in ALXN in Q3 2020 and held it in 1 quarter. The position peaked at $74K in Q3 2020. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Platinum Investment Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Platinum Investment Management sold 646 Alexion Pharmaceuticals shares in Q4 2020, an estimated $74K.
  • Platinum Investment Management first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Platinum Investment Management's Alexion Pharmaceuticals position peaked at $74K in Q3 2020.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Platinum Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.